| |
|
Diversified Communication Services News
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
1 hour, 1 minute ago (PR Newswire)
Amsterdam Molecular Therapeutics , a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| Sponsor
Results |
Earn From 1.50% to 1.80% With GE Capital Corporation. Not An Offer Of Securities For Sale. GEInterestPlus.com | Buy Stocks for $4 No account or investment minimums. No inactivity fees. Start Today. www.sharebuilder.com | Us Cellular Read reviews for this business with directions, offers and more Chicago.Citysearch.com (What's This?) | |
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 675B | | Price
/ Earnings: | 27.3 | | Price
/ Book: | -6.3 | | Net
Profit Margin (mrq): | 5.7% | | Price
To Free Cash Flow (mrq): | 46.5 | | Return
on Equity: | 8.1% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.2% |
|